The firm said it is drawing up plans for its business in a post-pandemic world, planning the introduction of new testing panels and enhancing its respiratory panel.
The firm, in its development work, has multiplexed up to 57 different analytes, obtaining quantitative results using one cartridge and one patient sample, its CEO said.
With new platforms in its plans, Accelerate will target hospitals that have a bacterial identification method but want to add rapid susceptibility testing.
The funding supports the development of a four-hour electrochemical antimicrobial sensitivity test that can be used with commercially available panels.
